Viatris Appoints Hemanth J. Varghese as Chief Strategy Officer

Rhea-AI Summary

Viatris Inc. (VTRS) has appointed Hemanth J. Varghese as Chief Strategy Officer, joining the Company's Executive Leadership Team. Varghese brings over 20 years of experience in strategy, operations, and corporate development within healthcare companies.

Prior to this appointment, Varghese served as President and COO at Venus Concept, SVP of Strategy & Operations at HLS Therapeutics, and held executive positions at Endo International, Valeant Pharmaceuticals, and Bausch & Lomb. He holds a bachelor's degree and Ph.D. in medical biophysics from the University of Western Ontario and is a Chartered Financial Analyst.

CEO Scott A. Smith expressed confidence that Varghese's expertise will be important for Viatris's growth strategy in 2026 and beyond.

Positive

• Strategic hire brings 20+ years of healthcare industry experience
• New CSO has extensive background in growth initiatives and strategic transformations
• Appointment strengthens executive leadership team with additional expertise in operations and corporate development

Negative

• None.

PITTSBURGH, April 14, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that Hemanth J. Varghese has joined the Company as Chief Strategy Officer. Varghese will be a member of the Company's Executive Leadership Team.

Varghese is an accomplished healthcare leader with more than 20 years of strategy, operations and corporate development experience. He brings broad experience leading growth initiatives and strategic transformations in diversified multi-national healthcare companies.

Prior to joining Viatris, Varghese was President and Chief Operating Officer at Venus Concept, an innovative global medical aesthetic technology company. He previously served as Senior Vice President, Strategy & Operations at HLS Therapeutics. He also held multiple roles at Endo International, including Executive Vice President, Corporate Development & Strategy and President, International Pharmaceuticals, several roles of increasing responsibility at Valeant Pharmaceuticals and Bausch & Lomb, and worked in corporate development at Biovail Corporation. Varghese earned a bachelor's degree and a Ph.D. in medical biophysics from the University of Western Ontario in Ontario, Canada, and is a Chartered Financial Analyst.

"We are excited to welcome Hemanth to Viatris in the role of Chief Strategy Officer," said Scott A. Smith, CEO, Viatris. "Hemanth adds another valuable perspective to our Executive Leadership Team. I believe his skills and expertise will be integral as we continue to shape our company for growth in 2026 and beyond."

"I am honored to be joining Viatris at such a transformative time for the company," said Varghese. "I'm looking forward to partnering with Scott, the Executive Leadership Team and others across the organization as we continue to build a strong company for the future."

About Viatris
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter).

Forward-Looking Statements
This statement includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements regarding the company's future, including growth in 2026 and beyond. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; Viatris' failure to achieve expected or targeted future financial and operating performance and results; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, tariffs and trade policies, inflation and exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/viatris-appoints-hemanth-j-varghese-as-chief-strategy-officer-302427162.html

SOURCE Viatris Inc.

FAQ

Who is the new Chief Strategy Officer at Viatris (VTRS)?

Hemanth J. Varghese has been appointed as Viatris's new Chief Strategy Officer, joining the Executive Leadership Team.

What is Hemanth Varghese's experience before joining Viatris (VTRS)?

Varghese has over 20 years of healthcare experience, previously serving as President and COO at Venus Concept, SVP at HLS Therapeutics, and executive roles at Endo International, Valeant Pharmaceuticals, and Bausch & Lomb.

What are Viatris's (VTRS) growth plans following this appointment?

The appointment is part of Viatris's strategy to shape the company for growth in 2026 and beyond, according to CEO Scott A. Smith.

What are Hemanth Varghese's educational qualifications for the VTRS position?

Varghese holds a bachelor's degree and Ph.D. in medical biophysics from the University of Western Ontario and is a Chartered Financial Analyst.